AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

被引：4
|
作者：
Strickler, J. H. [1 ]
Fakih, M. [2 ]
Price, T. J. [3 ]
Desai, J. [4 ]
Durm, G. [5 ]
Krauss, J. C. [6 ]
Kuboki, Y. [7 ]
Kim, T. W. [8 ]
Sacher, A. [9 ]
Henary, H. [10 ]
Kim, J. [11 ]
Hong, D. S. [12 ]
机构：
[1] Duke Canc Ctr, Med, Durham, NC USA
[2] City Hope Natl Med Ctr, Med Oncol & Therapeut Res, Duarte, CA USA
[3] Queen Elizabeth Hosp, Emergency Dept, Med Oncol, Woodville, SA, Australia
[4] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[5] Dept Med, Div Hematol Oncol, Indianapolis, IN USA
[6] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[7] Canc Inst Hosp JFCR, Dept Expt Therapeut & GI Oncol, Tokyo, Japan
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[9] Princess Margaret Canc Ctr, Med Oncol & Hematol Dept, Toronto, ON, Canada
[10] Amgen Inc, Early Dev Oncol Dept, Thousand Oaks, CA USA
[11] Amgen Inc, Biostat, Thousand Oaks, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeuitcs Dept, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
83MO
引用
收藏
页码：S1274 / S1275
页数：2
相关论文
共 34 条
  • [21] Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
    Gong, J.
    Lemech, C.
    Day, D.
    Shan, J.
    Morris, M.
    Nagrial, A.
    Chen, M.
    Huang, X.
    Zong, H.
    Wang, N.
    Yang, Y.
    Yi, T.
    Li, W.
    Zhuang, Z.
    Li, Z.
    Liu, Z.
    Luo, Y.
    Zhang, Y.
    Zhou, H.
    Shen, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S467 - S468
  • [22] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
    Skoulidis, Ferdinandos
    De langen, Adrianus
    Paz-Ares, Luis G.
    Mountzios, Giannis Socrates
    Curioni-Fontecedro, Alessandra
    Couraud, Sebastien
    Janssens, Annelies
    Rocco, Danilo
    Ohashi, Kadoaki
    Vincent, Mark David
    Kang, Jin-Hyoung
    Schvartsman, Gustavo
    Lindsay, Colin R.
    O'Byrne, Kenneth John
    Dziadziuszko, Rafal
    Andersen, Jon A. Lykkegaard
    Hindoyan, Antreas
    Wilmanski, Tomasz
    Wang, Yang
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial.
    Nakamura, Yoshiaki
    Esaki, Taito
    Nishina, Tomohiro
    Komatsu, Yoshito
    Yuki, Satoshi
    Shinozaki, Eiji
    Taniguchi, Hiroya
    Kato, Takeshi
    Kato, Ken
    Nomura, Shogo
    Ikeno, Takashi
    Ishiguro, Yukiko
    Takahashi, Koji
    Higuchi, Tsukiko
    Sato, Akihiro
    Odegaard, Justin Iver
    Kuwata, Takeshi
    Matsushima, Kouji
    Nakatsura, Tetsuya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 98 - 98
  • [24] Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation
    Cho, B. C.
    Shen, Y.
    Li, Z.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Liu, Y.
    Rui, H.
    Chen, J. Q.
    Wang, A. H.
    Zhang, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1642 - S1643
  • [25] Evaluation of acquired resistance to sotorasib in patients with KRAS p.G12C-mutated non-small cell lung cancer: biomarker analysis using plasma from the CodeBreaK 100 trial
    Addeo, A.
    Wolf, J.
    Li, B. T.
    Velcheti, V.
    Dy, G. K.
    Ramalingam, S. S.
    Hindoyan, A.
    Anderson, A.
    Ang, A.
    Skoulidis, F.
    Delord, J.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S24 - S24
  • [26] Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).
    Spira, Alexander I.
    Wilson, Frederick Hugh
    Shapiro, Geoffrey
    Dooms, Christophe
    Curioni-Fontecedro, Alessandra
    Esaki, Taito
    Barlesi, Fabrice
    Cocks, Kim
    Trigg, Andrew
    Stevinson, Kendall
    Matsuda, Tara
    Tran, Qui
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
    Sabari, Joshua K.
    Park, Haeseong
    Tolcher, Anthony W.
    Ou, Sai-Hong Ignatius
    Garon, Edward B.
    George, Ben
    Janne, Pasi A.
    Moody, Susan Elizabeth
    Tan, Eugene Y.
    Sen, Suman Kumar
    Peters, Dana
    Yan, Xiaohong
    Christensen, James G.
    Chi, Andrew S.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer.
    Skoulidis, Ferdinandos
    Li, Bob T.
    Govindan, Ramaswamy
    Dy, Grace K.
    Shapiro, Geoffrey
    Bauml, Joshua
    Schuler, Martin H.
    Addeo, Alfredo
    Kato, Terufumi
    Besse, Benjamin
    Anderson, Abraham
    Ang, Agnes
    Ngarmchamnanrith, Gataree
    Tran, Qui
    Velcheti, Vamsidhar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
    Cheng, X.
    Song, Z.
    Yao, J.
    Yang, J.
    Wang, M.
    Zhou, H.
    Sun, T.
    Wang, Q.
    Wu, L.
    Miao, J.
    Mi, Y.
    Lin, J.
    Zhao, H.
    Xing, S.
    Wu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S504 - S504
  • [30] A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy
    Ramesh K. Ramanathan
    Joe J. Stephenson
    Glen J. Weiss
    Linda A. Pestano
    Ann Lowe
    Alton Hiscox
    Rafael A. Leos
    Julie C. Martin
    Lynn Kirkpatrick
    Donald A. Richards
    Investigational New Drugs, 2012, 30 : 1591 - 1596
1234